Single-Use Bioreactors Market by Product (Single-Use Bioreactors System, Single-Use Media Bag, Single-Use Filtration Assemblies, Other),), Molecule Type (Monoclonal Antibodies, Vaccine, Stem Cells, Gene Modified Cells, Other Molecules), Cell Type (Mammalian Cells, Bacteria Cells, Yeast Cells, Other Cells), Application (Research and Development, Process Development, BioProduction, Other), End-User (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs)): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00027079 | Pages: 100 | Industry: Biotechnology | Date: Oct 2022 | Type: Global

The market is expected to cross the US$ 2.93 billion mark in 2022 and is expected to hit US$ 13.25 billion by 2030, recording a CAGR of 20.8% during the forecast period.

The techno developments in single-use Bioreactors are influencing the growth of the market.

Single-use bioreactors have the most significant impact as an alternative to cleanable, reusable systems. In March 2021, Thermo Fisher Scientific Launched 3,000 L and 5,000 L HyPerforma DynaDrive Single-Use Bioreactors for Cell Culture Production, enabling biopharmaceutical companies to integrate single-use technologies into large-scale bioprocesses, including perfusion cell culture manufacturing at a very high cell density. Thus, the significant developments in the single-use bioreactor segment will fuel the market growth.

The report segments the market into product, molecular, cell type, application, end-user, and geography. Based on product, the global single-use bioreactors market is segmented into single-use bioreactors systems, single-use media bags, and single-use filtration assemblies. Based on type, the market is categorized into stirred tank single-use bioreactors, bubble column single-use bioreactors, and wave-induced single-use bioreactors. Based on molecular type, the market is segmented into monoclonal antibodies, vaccines, stem cells, gene-modified cells, and other molecules. The market is categorized into mammalian, bacteria, yeast, and other cells based on cell type. The market is segmented based on application: research and development, process development, bioproduction, and others. Based on end-users, the market is segmented into pharmaceutical and biopharmaceutical companies, academic and research institutes, contract research organizations (CROs), and contract manufacturing organizations (CMOs). Geographically, the market is sub-segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Get more information on this report :

Increasing  R&D activities, and strategic partnerships are fueling the growth of the market.

A surge in R&D activities, strategic partnerships, collaborations, and elevated demand for new vaccines and therapeutics are driving market growth. For instance, In January 2022, HaemaLogiX Ltd (HaemaLogiX) and Lonza entered into a strategic initiative to manufacture the drug candidate for next clinical batch (cGMP) of HaemaLogiX's lead multiple myeloma. Such strategies for developing monoclonal antibodies are anticipated to create demand for single-use bioreactors, thereby expected to drive the growth of the market during the forecast period

The advantages of single-use bioreactors accelerate the market growth.

The advantages of single-use bioreactors have aided biotech drugs in reaching the market swiftly. Single-use bioreactors' advantages increased manufacturing flexibility, reduced ca,pital investment, and enhanced sterility assurance. For instance, Mobius, the Single-Use Bioreactor, is a scalable portfolio of stirred tank bioreactors that provides flexibility by configuring software, hardware, and single-use assemblies for use in fed-batch and perfusion applications. Also, the bioreactor is designed with intuitive software, semi-automated bioreactor inflation, integrated tubing management and labeled connections to reduce operating errors.

Recent strategic developments single-use bioreactors market

The single-use bioreactors market has undergone several significant developments, and a few of these have been mentioned below:

  • In May 2022, RD-Biotech, a Contract Research Organization (CRO) specializing in the production of plasmid DNA (pDNA) for early-phase clinical trials partnered with Pall Corporation to supply single-use solutions and purification technology to support the manufacture of industrially relevant volumes of GMP-grade pDNA.
  • In March,2020, Sartorius launched BIOSTAT STR Generation 3 with BIOBRAIN—making biopharmaceutical development and production faster, simpler and safer
  • In 2019, Pall Corporation partnered with Freeline to implement the iCELLis bioreactor system in Freeline’s adeno-associated virus (AAV) manufacturing platform. This partnership aims to achieve commercial scale and quality production of AAV gene therapy vectors.

Several players drive the single-use bioreactors market by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. ABEC, INC; Celltainer; Distek Inc; Thermo Fisher Scientific Inc; Eppendorf SE; Danaher; Merck KGaA; OmniBRx Biotechnologies; Pall Corporation; and Sartorius AG are the prominent players operating in the market.

Target audience for the report:

  • Raw material providers
  • Government bodies, such as regulating authorities and policy makers
  • Venture capitalists, private equity firms, and start-up companies
  • End users
  • Life Science and medical device companies
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented based on:

  • Product:
    • Single-Use Bioreactors System
    • Single-Use Media Bag
    • Single-Use Filtration Assemblies
    • Other
  • Type:
    • Stirred Tank Single-Use Bioreactors
    • Bubble Column Single-Use Bioreactors
    • Wave Induced Single-Use Bioreactors
  • Molecular Type:
    • Monoclonal Antibodies
    • Vaccine
    • Stem Cells
    • Gene Modified Cells
    • Other
  • Cell Type:
    • Mammalian Cells
    • Bacteria Cells
    • Yeast Cells
    • Other Cells
  • Application:
    • Research and Development
    • Process Development
    • BioProduction
    • Other
  • End-User:
    • Pharmaceutical and Biopharmaceutical Companies
    • Academic and Research Institutes
    • Contract Research Organizations (CROs)
    • Contract Manufacturing Organizations (CMOs)
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
    • ABEC, INC.
    • Celltainer
    • Distek Inc.
    • Thermo Fisher Scientific Inc.
    • Eppendorf SE
    • Danaher
    • Merck KGaA
    • OmniBRx Biotechnologies
    • Pall Corporation
    • Sartorius AG

The List of Companies
- ABEC, INC.
- Celltainer
- Distek Inc.
- Thermo Fisher Scientific Inc.
- Eppendorf SE
- Danaher
- Merck KGaA
- OmniBRx Biotechnologies
- Pall Corporation
- Sartorius AG


Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$1500
Site License
$2500
Enterprise License
$3500